A detailed history of Deutsche Bank Ag\ transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 62,694 shares of RVNC stock, worth $161,123. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,694
Previous 37,061 69.16%
Holding current value
$161,123
Previous $95,000 69.47%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.57 - $2.57 $65,876 - $65,876
25,633 Added 69.16%
62,694 $161,000
Q2 2024

Aug 14, 2024

SELL
$2.34 - $4.73 $19,581 - $39,580
-8,368 Reduced 18.42%
37,061 $95,000
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $5,240 - $10,492
1,127 Added 2.54%
45,429 $223,000
Q4 2023

Feb 14, 2024

SELL
$5.81 - $11.2 $4,299 - $8,288
-740 Reduced 1.64%
44,302 $389,000
Q3 2023

Nov 09, 2023

BUY
$11.47 - $25.07 $59,644 - $130,364
5,200 Added 13.05%
45,042 $516,000
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $436,597 - $664,794
-17,676 Reduced 30.73%
39,842 $1.01 Million
Q1 2023

May 15, 2023

SELL
$18.36 - $35.27 $1.85 Million - $3.56 Million
-100,801 Reduced 63.67%
57,518 $1.85 Million
Q4 2022

Feb 13, 2023

BUY
$18.32 - $30.66 $2.31 Million - $3.86 Million
125,982 Added 389.59%
158,319 $2.92 Million
Q3 2022

Nov 14, 2022

SELL
$14.33 - $28.47 $123,467 - $245,297
-8,616 Reduced 21.04%
32,337 $873,000
Q2 2022

Aug 11, 2022

SELL
$11.52 - $20.4 $55,399 - $98,103
-4,809 Reduced 10.51%
40,953 $566,000
Q1 2022

May 13, 2022

SELL
$12.36 - $20.31 $60,539 - $99,478
-4,898 Reduced 9.67%
45,762 $892,000
Q4 2021

Feb 11, 2022

BUY
$12.46 - $27.87 $34,439 - $77,032
2,764 Added 5.77%
50,660 $827,000
Q3 2021

Nov 04, 2021

SELL
$25.78 - $33.21 $381,311 - $491,209
-14,791 Reduced 23.6%
47,896 $1.33 Million
Q2 2021

Aug 11, 2021

SELL
$26.8 - $31.84 $2.06 Million - $2.44 Million
-76,766 Reduced 55.05%
62,687 $1.86 Million
Q1 2021

May 13, 2021

BUY
$24.03 - $29.97 $2.14 Million - $2.67 Million
89,178 Added 177.38%
139,453 $3.9 Million
Q4 2020

Feb 16, 2021

BUY
$23.41 - $28.34 $293,022 - $354,731
12,517 Added 33.15%
50,275 $1.42 Million
Q3 2020

Nov 12, 2020

SELL
$23.23 - $34.3 $2.25 Million - $3.32 Million
-96,809 Reduced 71.94%
37,758 $949,000
Q2 2020

Aug 13, 2020

SELL
$12.6 - $26.55 $520,317 - $1.1 Million
-41,295 Reduced 23.48%
134,567 $3.29 Million
Q1 2020

May 14, 2020

BUY
$12.46 - $27.81 $251,069 - $560,371
20,150 Added 12.94%
175,862 $2.6 Million
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $1.45 Million - $2.51 Million
124,438 Added 397.9%
155,712 $2.53 Million
Q3 2019

Nov 14, 2019

SELL
$10.22 - $14.5 $4.85 Million - $6.88 Million
-474,262 Reduced 93.81%
31,274 $404,000
Q2 2019

Aug 14, 2019

BUY
$10.67 - $15.49 $371,198 - $538,881
34,789 Added 7.39%
505,536 $6.56 Million
Q1 2019

May 15, 2019

BUY
$15.4 - $20.39 $2.14 Million - $2.83 Million
138,927 Added 41.87%
470,747 $7.42 Million
Q4 2018

Feb 14, 2019

BUY
$18.06 - $24.96 $1.77 Million - $2.45 Million
98,257 Added 42.07%
331,820 $6.68 Million
Q3 2018

Dec 21, 2021

BUY
$23.55 - $30.1 $328,192 - $419,473
13,936 Added 6.35%
233,563 $5.8 Million
Q3 2018

Nov 14, 2018

SELL
$23.55 - $30.1 $1.83 Million - $2.34 Million
-77,893 Reduced 26.18%
219,627 $5.46 Million
Q2 2018

Apr 21, 2020

BUY
$27.45 - $33.35 $459,128 - $557,812
16,726 Added 5.96%
297,520 $8.17 Million
Q2 2018

Aug 14, 2018

BUY
$27.45 - $33.35 $3.1 Million - $3.77 Million
113,055 Added 67.4%
280,794 $7.71 Million
Q1 2018

Oct 18, 2019

BUY
$29.15 - $37.4 $435,267 - $558,456
14,932 Added 9.77%
167,739 $5.17 Million
Q1 2018

May 15, 2018

BUY
$29.15 - $37.4 $708,898 - $909,530
24,319 Added 18.93%
152,807 $4.71 Million
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $343,994 - $508,635
14,012 Added 12.24%
128,488 $4.59 Million
Q3 2017

Nov 14, 2017

BUY
$22.55 - $28.1 $2.58 Million - $3.22 Million
114,476
114,476 $3.15 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.